CareDx Study Links dd-cfDNA Elevations to Long-Term Kidney Transplant Outcomes
Event summary
- CareDx published a KOAR study in JASN showing dd-cfDNA elevations predict kidney allograft outcomes.
- Analysis of 1,258 patients found a 3.7x and 6.4x higher risk of allograft loss for intermediate and high dd-cfDNA states.
- 36% of patients experienced dd-cfDNA elevation while kidney function remained preserved.
- Persistently low dd-cfDNA levels correlated with favorable long-term outcomes.
The big picture
This study strengthens CareDx's position in precision medicine for transplant monitoring, particularly as payers increasingly demand evidence of long-term clinical utility. The findings support dd-cfDNA's role in early intervention, aligning with broader trends toward proactive transplant management. CareDx's ability to commercialize this data will depend on demonstrating cost-effectiveness in real-world settings.
What we're watching
- Clinical Adoption
- How quickly nephrologists integrate longitudinal dd-cfDNA monitoring into standard care protocols.
- Regulatory Pathway
- Whether these findings accelerate AlloSure's path to expanded FDA approval for risk stratification.
- Competitive Positioning
- The pace at which CareDx can differentiate AlloSure from emerging kidney transplant biomarkers.
Related topics